A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China

Key Points

• Abemaciclib showed consistent effectiveness in treating HR+/HER2- breast cancer, indicating a favorable benefit-risk profile.
• Participants in the analysis included adults with early and advanced breast cancer who received abemaciclib for treatment.
• This observational study evaluated the safety and tolerability of abemaciclib, validating its use in a real-world context.
• The findings support the continued use of abemaciclib, emphasizing its positive real-world outcomes without new safety concerns.